https://www.selleckchem.com/pr....oducts/p5091-p005091
Carbapenem-resistant organisms (CROs) pose great challenges for clinical treatment. Polymyxin B (PM is one of the "last resort" choices of CRO infections. We explored the possible factors affecting PMB efficacy. This retrospective study involved CRO-infected patients treated with PMB for ≥72 h. The endpoint indicator was clinical efficacy. We compared the characteristics (demographics, pathogenic bacteria, PMB treatment) between patients who had "clinical success" (CS) and "clinical failure" (CF). A total of 191 patients were en
Like
Comment
Share
